Invivyd, Inc. (IVVD): Shareholders' Equity
$241.54M
As of 2025-12-31
$181.08M
As of 2026-06-30
-12.1%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $241.54M | +257.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $67.54M | -61.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $177.47M | -50.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $355.97M | -36.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $558.02M | n/m | 2023-03-23, Balance as of period end |
| 2020-12-31 | -$65.25M | n/a | 2022-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $48.23M | +11.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
Compare IVVD, PLX, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗